Doina Ionescu has been named as the new managing director and general manager for the Merck Healthcare business in the UK and Republic of Ireland. The move follows...

With supply constraints loosening late last year, GlaxoSmithKline’s shingles vaccine Shingrix was finally ready to jet ahead. Then COVID-19 happened, sparking a new ...

That didn’t take long. Just days after resubmitting its application to the FDA, Merck nabbed an approval Tuesday for a new, more convenient Keytruda dosing regimen ...

When the novel coronavirus was first identified in China and put the entire country on high alert, there were concerns that the outbreak would hit AstraZeneca hard, ...

Since late 2018, women with ovarian cancer who responded to an initial round of chemo have been eligible to receive a PARP inhibitor, but only if they had a BRCA mut...

The majority of pharmacists are unable to maintain social distancing at work and one in three are still not able to get continuous supplies of Personal Protective Eq...

AstraZeneca and Saint Luke’s Mid America Heart Institute have kicked off a randomised, global Phase III trial to assess the potential of Farxiga (dapagliflozin) as a...

At first glance, Roche’s business has been steady during the COVID-19 crisis. But below the surface, executives still warn of volatilities, though not all of them ar...

Bristol Myers Squibb and Exelixis have a potential kidney cancer contender on their hands—but they’ll have to meet a “high bar” to gain traction in the crowded field...